Cover ImageSALE
市場調查報告書

肝細胞癌症 (HCC):流行病學預測 (∼2027年)

Hepatocellular Carcinoma (HCC) - Epidemiology Forecast to 2027

出版商 DelveInsight Business Research LLP 商品編碼 534916
出版日期 內容資訊 英文 92 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肝細胞癌症 (HCC):流行病學預測 (∼2027年) Hepatocellular Carcinoma (HCC) - Epidemiology Forecast to 2027
出版日期: 2018年06月01日 內容資訊: 英文 92 Pages
簡介

主要8個國家 (G8:美國·法國·德國·義大利·西班牙·英國·日本·中國) 的肝細胞癌症整體發病數量,預測在2016年時將達到458,170件。

本報告提供全球主要8個國家 (G8) 的肝細胞癌症 (HCC)的流行病學預測相關分析,提供疾病概要和目前治療手法/演算法,全球整體及各國的患病人數與風險患者趨勢預測 (今後10年份),治療藥的各選擇狀況 (第一/第二選擇療法)的詳細趨勢等相關調查。

第1章 主要考察

第2章 疾病的背景情況和概要:肝細胞癌症 (HCC)

  • 簡介
  • 症狀
  • 肝細胞癌症的病期分類法 (癌症分期)
    • Okuda分類
    • French分類
    • CLIP評分
    • CUPI評分
    • TNM階段
    • JIS癌症分期
    • BCLC病期分類系統
  • 疾病和風險因素
  • 病理生理學
  • 診斷方法
    • AASLD (美國肝臟學會議)的,肝細胞癌症 (HCC)的監視·診斷相關診療指南
    • EASL-EORTC (歐洲肝臟學會/歐洲癌症研究治療機關)的,肝細胞癌症 (HCC)的監視·診斷相關診療指南
    • 日本的「科學性實證肝癌症診療指南」
    • NCCN (全美綜合癌症中心網路)的臨床治療指南

第3章 流行病學和患者人口

第4章 分析的要點

第5章 患者人口與預測變數

  • 主要8個國家 (G8)的肝細胞癌症發病數量總數
  • 主要8個國家 (G8)的進行性肝細胞癌症的確診患者數
  • 實施中的患者總數第一選擇療法
  • 實施中的患者總數第二選擇療法

第6章 各國的流行病學情形:肝細胞癌症 (HCC)

  • 美國
    • 肝細胞癌症的發病數量總數
    • 肝細胞癌症的確診患病人數
    • 患者總數:各治療法
    • 患者總數:治療方法的各選擇狀況
  • (EU5)的市場分析歐洲5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 中國

第7章 附錄

第8章 分析方法

  • 資訊來源

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0351

DelveInsight's 'Hepatocellular Carcinoma (HCC) - Epidemiology Forecast to 2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Hepatocellular Carcinoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), China and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • China

Study Period: 2016-2027

Hepatocellular Carcinoma Epidemiology

The Hepatocellular Carcinoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. The epidemiology data for Hepatocellular Carcinoma are studied through all possible division to give a better understanding about the Disease scenario in G8 countries. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Hepatocellular Carcinoma Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases, diagnosed incidence of advanced HCC, total patients on therapies (patients by line of therapies) scenario of Hepatocellular Carcinoma in the G8 covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), China and Japan from 2016-2027.

The DelveInsight report also provides the epidemiology trends observed in the G8 countries during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of incident cases of Hepatocellular Carcinoma was found to be 458,170, in the year 2016 in G8 countries.

Report Scope

  • The report covers detailed overview of Hepatocellular Carcinoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Hepatocellular Carcinoma in 8 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), China & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the G8 with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by diagnosed advanced HCC, and patients by line of therapies (first line and second line of therapies) in G8 countries.

Key strengths

  • 10 Year Forecast of Hepatocellular Carcinoma epidemiology
  • G8 Coverage
  • Total Incident Cases of HCC
  • Incident Cases according to segmentation: Patients by line of therapies (first line and second line of therapies)
  • Diagnosed cases of HCC

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview: Hepatocellular Carcinoma

  • 2.1. Introduction
  • 2.2. Signs and Symptoms
  • 2.3. Staging of Hepatocellular Carcinoma
    • 2.3.1. Okuda Stage
    • 2.3.2. French Classification
    • 2.3.3. CLIP Score
    • 2.3.4. CUPI Score
    • 2.3.5. TNM Stage
    • 2.3.6. JIS Staging
    • 2.3.7. BCLC Staging System
  • 2.4. Etiology and Risk Factors
  • 2.5. Pathophysiology
  • 2.6. Diagnosis
    • 2.6.1. AASLD practice guidelines for HCC surveillance and diagnosis
    • 2.6.2. EASL-EORTC practice guidelines for HCC surveillance and diagnosis
    • 2.6.3. Japanese evidence-based clinical practice guidelines for HCC
    • 2.6.4. NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines

3. Epidemiology and Patient Population

4. Key Findings

5. Population and Forecast Parameters

  • 5.1. Total Incident Cases of HCC in G8 countries
  • 5.2. Total Diagnosed Advanced HCC cases in G8 countries
  • 5.3. Total Patients on First-Line Therapies
  • 5.4. Total Patients on Second-Line Therapies

6. Country Wise-Epidemiology of HCC

  • 6.1. United States
    • 6.1.1. Total Incident cases of HCC in the United States
    • 6.1.2. Total Diagnosed Advanced HCC cases in the United States
    • 6.1.3. Total Patients on Therapies
    • 6.1.4. Total Patients By Line of Therapies in the United States
  • 6.2. EU5 Countries
  • 6.3. Germany
    • 6.3.1. Total Incident cases of HCC in Germany
    • 6.3.2. Total Diagnosed Advanced HCC cases in Germany
    • 6.3.3. Total Patients on Therapies
    • 6.3.4. Total Patients By Line of Therapies in Germany
  • 6.4. France
    • 6.4.1. Total Incident cases of HCC in France
    • 6.4.2. Total Diagnosed Advanced HCC cases in France
    • 6.4.3. Total Patients on Therapies
    • 6.4.4. Total Patients By Line of Therapies in France
  • 6.5. Italy
    • 6.5.1. Total Incident cases of HCC in Italy
    • 6.5.2. Total Diagnosed Advanced HCC cases in Italy
    • 6.5.3. Total Patients on Therapies
    • 6.5.4. Total Patients By Line of Therapies in Italy
  • 6.6. Spain
    • 6.6.1. Total Incident cases of HCC in Spain
    • 6.6.2. Total Diagnosed Advanced HCC cases in Spain
    • 6.6.3. Total Patients on Therapies
    • 6.6.4. Total Patients By Line of Therapies in Spain
  • 6.7. United Kingdom
    • 6.7.1. Total Incident cases of HCC in the United Kingdom
    • 6.7.2. Total Diagnosed Advanced HCC cases in the United Kingdom
    • 6.7.3. Total Patients on Therapies
    • 6.7.4. Total Patients By Line of Therapies in the UK
  • 6.8. Japan
    • 6.8.1. Total Incident cases of HCC in Japan
    • 6.8.2. Total Diagnosed Advanced HCC cases in Japan
    • 6.8.3. Total Patients on Therapies
    • 6.8.4. Total Patients By Line of Therapies in Japan
  • 6.9. China
    • 6.9.1. Total Incident cases of HCC in China
    • 6.9.2. Total Diagnosed Advanced HCC cases in China
    • 6.9.3. Total Patients on Therapies
    • 6.9.4. Total Patients By Line of Therapies in China

7. Appendix

8. Report Methodology

  • 8.1. Sources Used

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1: Molecular targeted therapies under evaluation in Phase II or III randomized controlled trials in HCC
  • Table 2: Total Incident Cases of HCC in G8 countries (2016-2027)
  • Table 3: Total Diagnosed Advanced HCC cases in G8 (2016-2027)
  • Table 4: Total Patients on First-Line Therapies in G8 (2016-2027)
  • Table 5: Total Patients on Second-Line Therapies in G8 (2016-2027)
  • Table 6: Total Incident Cases of HCC in the United States (2016-2027)
  • Table 7: Total Diagnosed Advanced HCC cases in the United States (2016-2027)
  • Table 8: Total Patients on Therapies in the United States (2016-2027)
  • Table 9: Patients By Line of Therapies in the United States (2016-2027)
  • Table 10: Total Incident Cases of HCC in Germany (2016-2027)
  • Table 11: Total Diagnosed Advanced HCC cases in Germany (2016-2027)
  • Table 12: Total Patients on Therapies in Germany (2016-2027)
  • Table 13: Patients By Line of Therapies in Germany (2016-2027)
  • Table 14: Total Incident Cases of HCC in France (2016-2027)
  • Table 15: Total Diagnosed Advanced HCC cases in France (2016-2027)
  • Table 16: Total Patients on Therapies in France (2016-2027)
  • Table 17: Patients by Line of Therapies in France (2016-2027)
  • Table 18: Total Incident Cases of HCC in Italy (2016-2027)
  • Table 19: Total Diagnosed Advanced HCC cases in Italy 2016-2027)
  • Table 20: Total Patients on Therapies in Italy (2016-2027)
  • Table 21: Patients By Line of Therapies in the Italy (2016-2027)
  • Table 22: Total Incident Cases of HCC in Spain (2016-2027)
  • Table 23: Total Diagnosed Advanced HCC cases in Spain (2016-2027)
  • Table 24: Total Patients on Therapies in Spain (2016-2027)
  • Table 25: Patients By Line of Therapies in Spain (2016-2027)
  • Table 26: Total Incident Cases of HCC in the United Kingdom (2016-2027)
  • Table 27: Total Diagnosed Advanced HCC cases in the United Kingdom (2016-2027)
  • Table 28: Total Patients on Therapies in the United Kingdom (2016-2027)
  • Table 29: Patients By Line of Therapies in the United Kingdom (2016-2027)
  • Table 30: Total Incident Cases of HCC in Japan (2016-2027)
  • Table 31: Total Diagnosed Advanced HCC cases in Japan (2016-2027)
  • Table 32: Total Patients on Therapies in Japan (2016-2027)
  • Table 33: Patients By Line of Therapies in Japan (2016-2027)
  • Table 34: Total Incident Cases of HCC in China (2016-2027)
  • Table 35: Total Diagnosed Advanced HCC cases in China (2016-2027)
  • Table 36: Total Patients on Therapies in China (2016-2027)
  • Table 37: Patients By Line of Therapies in China (2016-2027)

List of Figures

  • Figure 1: BCLC staging system and therapeutic strategy
  • Figure 2: Cancer progression and driver genes
  • Figure 3: Molecular targeted therapies for HCC and their target Signaling pathways
  • Figure 4: AASLD practice guidelines for HCC surveillance and diagnosis
  • Figure 5: EASL-EORTC practice guidelines for HCC surveillance and diagnosis
  • Figure 6: Japanese evidence-based clinical practice guidelines for HCC: surveillance and diagnostic algorithm
  • Figure 7:NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines for Diagnosis
  • Figure 8:NCCN Clinical practice Guidelines - When HCC is confirmed
  • Figure 9: Total Incident Cases of HCC in G8 countries (2016-2027)
  • Figure 10: Total Diagnosed Advanced HCC cases in G8 countries (2016-2027)
  • Figure 11: Total Patients on First-Line Therapies in the G8 (2016-2027)
  • Figure 12: Total Patients on Second-Line Therapies in the G8 (2016-2027)
  • Figure 13: Total Incident Cases of HCC in the United States (2016-2027)
  • Figure 14: Total Diagnosed Advanced HCC cases in the United States (2016-2027)
  • Figure 15: Total Patients on Therapies in the United States (2016-2027)
  • Figure 16: Patients by Line of Therapies in the United States (2016-2027)
  • Figure 17: Total Incident Cases of HCC in Germany (2016-2027)
  • Figure 18: Total Diagnosed Advanced HCC cases in Germany (2016-2027)
  • Figure 19: Total Patients on Therapies in Germany (2016-2027)
  • Figure 20: Patients by Line of Therapies in Germany (2016-2027)
  • Figure 21: Total Incident Cases of HCC in France (2016-2027)
  • Figure 22: Total Diagnosed Advanced HCC cases in France (2016-2027)
  • Figure 23: Total Patients on Therapies in France (2016-2027)
  • Figure 24: Patients by Line of Therapies in France (2016-2027)
  • Figure 25: Total Incident Cases of HCC in Italy (2016-2027)
  • Figure 26: Total Diagnosed Advanced HCC cases in Italy (2016-2027)
  • Figure 27: Total Patients on Therapies in Italy (2016-2027)
  • Figure 28: Patients by Line of Therapies in Italy (2016-2027)
  • Figure 29: Total Incident Cases of HCC in Spain (2016-2027)
  • Figure 30: Total Diagnosed Advanced HCC cases in Spain (2016-2027)
  • Figure 31: Total Patients on Therapies in Spain (2016-2027)
  • Figure 32: Patients By Line of Therapies in Spain (2016-2027)
  • Figure 33: Total Incident Cases of HCC in the United Kingdom (2016-2027)
  • Figure 34: Total Diagnosed Advanced HCC cases in the United Kingdom (2016-2027)
  • Figure 35: Total Patients on Therapies in the United Kingdom (2016-2027)
  • Figure 36: Patients By Line of Therapies in the United Kingdom (2016-2027)
  • Figure 37: Total Incident Cases of HCC in Japan (2016-2027)
  • Figure 38: Total Diagnosed Advanced HCC cases in Japan (2016-2027)
  • Figure 39: Total Patients on Therapies in Japan (2016-2027)
  • Figure 40: Patients By Line of Therapies in Japan (2016-2027)
  • Figure 41: Total Incident Cases of HCC in China (2016-2027)
  • Figure 42: Total Diagnosed Advanced HCC cases in China (2016-2027)
  • Figure 43: Total Patients on Therapies in China (2016-2027)
  • Figure 44: Patients by Line of Therapies in China (2016-2027)
Back to Top